Madrigal sells the first approved drug for MASH fatty-liver disease.
Madrigal Pharmaceuticals, Inc. (MDGL) is expected to report earnings on Tuesday, November 3, 2026, after the close. Estimated release time 07:04 ET. Consensus EPS estimate is $-0.86.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | FY2026 Q2 | $-2.68 | $-1.99 | +25.7% | $364.25M |
| 2026-05-06 | FY2026 Q1 | $-3.61 | $-3.25 | +10.0% | $311.34M |
| 2025-08-05 | FY2025 Q2 | $-3.48 | $-1.90 | +45.4% | $212.80M |
| 2025-05-01 | FY2025 Q1 | $-3.62 | $-3.32 | +8.3% | $137.25M |
| 2025-02-26 | FY2024 Q4 | — | $-2.71 | — | $103.32M |
| 2022-05-09 | FY2022 Q1 | $-3.75 | $-3.36 | +10.4% | $0 |
MDGL has beaten consensus EPS in 5 of its last 6 reported quarters.
Highlights from MDGL's Jul 30 report: EPS of -$1.99 — a big beat vs the -$2.68 estimate (+26%); revenue of $364M — a beat vs the $352M consensus (+3%). Focus now shifts to Rezdiffra launch trajectory.
See MDGL on the live calendar →